• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

直接作用抗病毒治疗后 HCV 单感染和 HCV/HIV 合并感染患者非侵入性肝纤维化标志物 24 个月的下降。

24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.

机构信息

Biochemistry and Molecular Biology Oviedo, School of Medicine, University of Oviedo, Oviedo, Spain.

Group of Translational Research in Infectious Diseases, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.

出版信息

Sci Rep. 2022 Mar 9;12(1):3828. doi: 10.1038/s41598-022-07548-y.

DOI:10.1038/s41598-022-07548-y
PMID:35264591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8907337/
Abstract

Long term liver fibrosis (LF) changes and their best -monitoring non-invasive markers (NILFM) after effective anti-HCV DAA therapy are little- known. Matrix-metalloproteases (MMPs) and their tissue-inhibitors (TIMPs) are pivotal in liver inflammation repair. Their plasma levels might assess long-term LF changes after therapy. Overall 374 HCV-infected adult patients, 214 HCV-HIV coinfected, were followed-up for 24 months after starting DAA. LF was assessed by transient elastometry (TE), biochemical indexes (APRI, Forns, FIB-4) and, in 61 individuals, by MMPs and TIMP-1 plasma levels. Several MMPs and TIMP-1 SNPs were genotyped in 319 patients. TE was better than biochemical indexes for early and long-term LF monitoring. MMPs-2,-8,-9 and-TIMP-1 levels and TE displayed parallel declining curves although only TIMP-1 correlated with TE (P = 0.006) and biochemical indexes (P < 0.02). HCV monoinfected had significantly higher baseline NILFM and TIMP-1 plasma values, but lower MMPs levels than coinfected patients. No differences in NILFM course were observed between mono-and coinfected or between different DAA regimens. Only the MMP-2 (-1306 C/T) variant TT genotype associated with higher values of NILFM NILFM decline extends 24 months after therapy. TE and TIMP1 are reliable LF-monitoring tools. NILFM courses were similar in mono-and coinfected patients, DAA regimens type did not influence NILFM course.

摘要

长期肝纤维化 (LF) 变化及其最佳监测非侵入性标志物 (NILFM) 在有效抗 HCV DAA 治疗后知之甚少。基质金属蛋白酶 (MMPs) 和它们的组织抑制剂 (TIMPs) 在肝脏炎症修复中起着关键作用。它们的血浆水平可能评估治疗后长期 LF 的变化。总体而言，374 名 HCV 感染的成年患者，214 名 HCV-HIV 合并感染患者，在开始 DAA 后进行了 24 个月的随访。LF 通过瞬时弹性成像 (TE)、生化指标 (APRI、Forns、FIB-4) 以及在 61 名个体中通过 MMPs 和 TIMP-1 血浆水平进行评估。319 名患者进行了几种 MMPs 和 TIMP-1 SNP 的基因分型。TE 比生化指标更适合早期和长期 LF 监测。MMPs-2、-8、-9 和 TIMP-1 水平和 TE 显示出平行下降曲线，尽管只有 TIMP-1 与 TE（P = 0.006）和生化指标（P < 0.02）相关。HCV 单感染患者的基线 NILFM 和 TIMP-1 血浆值明显更高，但 MMPs 水平较低。在单感染和合并感染患者之间或在不同的 DAA 方案之间，NILFM 过程没有差异。只有 MMP-2 (-1306 C/T) 变体 TT 基因型与较高的 NILFM 值相关，NILFM 下降持续 24 个月。TE 和 TIMP1 是可靠的 LF 监测工具。单感染和合并感染患者的 NILFM 过程相似，DAA 方案类型不影响 NILFM 过程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/d3516953f3eb/41598_2022_7548_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/54e6c4470b7b/41598_2022_7548_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/b21ef9401ded/41598_2022_7548_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/c1c0e68c069f/41598_2022_7548_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/a7b8dbcfa6e5/41598_2022_7548_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/ef92404dd089/41598_2022_7548_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/d3516953f3eb/41598_2022_7548_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/54e6c4470b7b/41598_2022_7548_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/b21ef9401ded/41598_2022_7548_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/c1c0e68c069f/41598_2022_7548_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/a7b8dbcfa6e5/41598_2022_7548_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/ef92404dd089/41598_2022_7548_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eb3b/8907337/d3516953f3eb/41598_2022_7548_Fig6_HTML.jpg

相似文献

1
24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy.直接作用抗病毒治疗后 HCV 单感染和 HCV/HIV 合并感染患者非侵入性肝纤维化标志物 24 个月的下降。
Sci Rep. 2022 Mar 9;12(1):3828. doi: 10.1038/s41598-022-07548-y.
2
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.在 HCV 单感染和 HCV/HIV 共感染患者中，DAA 治疗后非侵入性肝纤维化标志物 24 个月的进程中无性别差异。
Sci Rep. 2024 Mar 29;14(1):7534. doi: 10.1038/s41598-024-57845-x.
3
Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.丙型肝炎病毒（HCV）单一感染及人类免疫缺陷病毒（HIV）/HCV合并感染患者的肝纤维化：基质金属蛋白酶（MMPs）及其组织抑制剂（TIMPs）的失调以及HCV蛋白酶抑制剂的作用
Int J Mol Sci. 2016 Mar 26;17(4):455. doi: 10.3390/ijms17040455.
4
Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.双脱氧肌苷（ddI）与成人 HIV-HCV 合并感染患者的肝纤维化增加有关。
J Viral Hepat. 2012 Oct;19(10):685-93. doi: 10.1111/j.1365-2893.2012.01596.x. Epub 2012 Mar 15.
5
Treatment of chronic HCV genotype 1 coinfection.慢性丙型肝炎病毒1型合并感染的治疗。
Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4.
6
Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.丙型肝炎病毒-人类免疫缺陷病毒合并感染患者直接作用抗病毒治疗后肝纤维化和免疫特征的长期演变。
Clin Microbiol Infect. 2022 Apr;28(4):610.e1-610.e7. doi: 10.1016/j.cmi.2021.08.019. Epub 2021 Aug 28.
7
Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?人类免疫缺陷病毒（HIV）-丙型肝炎病毒（HCV）合并感染患者持续病毒学应答前后的肝纤维化：哪种非侵入性标志物最适合用于监测纤维化消退？
Clin Infect Dis. 2021 Aug 2;73(3):468-477. doi: 10.1093/cid/ciaa702.
8
Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES.直接作用抗病毒药物治疗乙型和丙型肝炎合并感染患者的丙型肝炎病毒学应答：来自 ERCHIVES 的结果。
Int J Infect Dis. 2020 Mar;92:184-188. doi: 10.1016/j.ijid.2020.01.025. Epub 2020 Jan 21.
9
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.开始基于马拉维若的抗逆转录病毒治疗后，HIV/丙型肝炎病毒合并感染患者的血清纤维化介质和非侵入性肝纤维化标志物无短期增加。
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):2083-8. doi: 10.1007/s10096-012-1546-5. Epub 2012 Jan 19.
10
Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.在接受抗逆转录病毒治疗的HIV-1与丙型肝炎病毒合并感染个体中，丙型肝炎病毒会导致与纤维化严重程度相关的I型干扰素相关损伤增加。
AIDS. 2017 Jun 1;31(9):1223-1234. doi: 10.1097/QAD.0000000000001455.

引用本文的文献

1
Hepatic Markers and Immunological Trajectories in a Cohort of Patients with HIV and Hepatitis C Virus Coinfection Treated with Direct-Acting Antivirals.一组接受直接抗病毒药物治疗的合并感染艾滋病毒和丙型肝炎病毒患者的肝脏标志物和免疫轨迹
AIDS Res Hum Retroviruses. 2025 Aug;41(8):400-410. doi: 10.1089/aid.2025.0001. Epub 2025 May 21.
2
No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.在 HCV 单感染和 HCV/HIV 共感染患者中，DAA 治疗后非侵入性肝纤维化标志物 24 个月的进程中无性别差异。
Sci Rep. 2024 Mar 29;14(1):7534. doi: 10.1038/s41598-024-57845-x.

本文引用的文献

1
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.EASL 临床实践指南：非侵入性检测评估肝脏疾病严重程度和预后——2021 更新版。
J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.
2
Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response.直接抗病毒药物诱导持续病毒学应答后，晚期纤维化慢性丙型肝炎患者存在持续性肝脏炎症。
J Chin Med Assoc. 2021 May 1;84(5):472-477. doi: 10.1097/JCMA.0000000000000517.
3
Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
丙型肝炎病毒治疗：化繁为简，优化难点。
J Infect Dis. 2020 Nov 27;222(Suppl 9):S745-S757. doi: 10.1093/infdis/jiaa534.
4
Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers-a role for MMP-9/TIMP-1.直接作用抗病毒药物治疗慢性丙型肝炎后肝纤维化改善伴随着促纤维化生物标志物的减少 - MMP-9/TIMP-1 的作用。
Dig Liver Dis. 2020 Oct;52(10):1170-1177. doi: 10.1016/j.dld.2020.05.004. Epub 2020 Jun 7.
5
Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?人类免疫缺陷病毒（HIV）-丙型肝炎病毒（HCV）合并感染患者持续病毒学应答前后的肝纤维化：哪种非侵入性标志物最适合用于监测纤维化消退？
Clin Infect Dis. 2021 Aug 2;73(3):468-477. doi: 10.1093/cid/ciaa702.
6
Noninvasive Markers for Monitoring Fibrosis Regression After Hepatitis C Virus Cure: What Do They Promise?丙型肝炎病毒治愈后监测纤维化消退的非侵入性标志物：它们有何前景？
Clin Infect Dis. 2021 Aug 2;73(3):478-479. doi: 10.1093/cid/ciaa698.
7
Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.接受直接抗病毒药物治疗的丙型肝炎患者非侵入性纤维化指数值迅速下降。
BMC Gastroenterol. 2019 Apr 27;19(1):63. doi: 10.1186/s12876-019-0973-5.
8
Correlations of MMP-2 and MMP-9 gene polymorphisms with the risk of hepatopulmonary syndrome in cirrhotic patients: A case-control study.基质金属蛋白酶-2 和基质金属蛋白酶-9 基因多态性与肝硬化患者肝肺综合征风险的相关性：一项病例对照研究。
Kaohsiung J Med Sci. 2018 Nov;34(11):634-642. doi: 10.1016/j.kjms.2018.06.006. Epub 2018 Jul 25.
9
Matrix Metalloproteinases (MMPs) in Liver Diseases.肝脏疾病中的基质金属蛋白酶（MMPs）
J Clin Exp Hepatol. 2017 Dec;7(4):367-372. doi: 10.1016/j.jceh.2017.09.004. Epub 2017 Oct 3.
10
Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment.直接作用抗病毒疗法治疗慢性丙型肝炎感染可导致治疗后 12 个月内肝硬度下降。
Dig Dis Sci. 2018 Feb;63(2):486-492. doi: 10.1007/s10620-017-4749-x. Epub 2017 Sep 8.